Lb Pharmaceuticals (LBRX) Change in Accured Expenses (2024 - 2026)

Lb Pharmaceuticals' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 219.7% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was -$390000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$910000.0, down 118.14% from the prior year.
• Change in Accured Expenses improved to $3.5 million in Q1 2026 per LBRX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.5 million in Q1 2026 and bottomed at -$2.9 million in Q4 2024.
• The 3-year median for Change in Accured Expenses is -$464500.0 (2025), against an average of -$97500.0.
• Across the five-year window, Change in Accured Expenses jumped 167.18% in 2025 and surged 219.7% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at -$2.9 million in 2024, then jumped by 167.18% to $2.0 million in 2025, then jumped by 76.28% to $3.5 million in 2026.
• Per Business Quant, the three latest LBRX Change in Accured Expenses figures stand at $3.5 million (Q1 2026), $2.0 million (Q4 2025), and -$2.9 million (Q1 2025).